An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy

Keyphrases

• Virus Vaccine 100%
• Brain Proteins 100%
• Experimental Stroke 100%
• Experimental Epilepsy 100%
• Adenovirus 100%
• Oral Vaccine 100%
• NMDAR1 100%
• Vaccination 50%
• Neurological Disorders 50%
• Cell-mediated Response 50%
• Brain Antigens 50%
• Immunological Response 50%
• Vaccination Strategy 50%
• Antiepileptic Drugs 50%
• Seizure Models 50%
• Single-dose Vaccine 50%
• Transient Middle Cerebral Artery Occlusion (tMCAO) 50%
• Neuroprotective Activity 50%
• Stroke Model 50%
• NR1 Subunit 50%
• N-methyl-D-aspartate Receptor (NMDAR) 50%
• Kainate-induced Seizure 50%
• Humoral Response 50%
• Transgene Expression 50%
• Peroral Administration 50%
• Therapeutic Potential 50%
• Neurological Autoimmunity 50%

Medicine and Dentistry

• Virus Vaccine 100%
• Experimental Stroke 100%
• Experimental Epilepsy 100%
• Oral Vaccine 100%
• Adeno-Associated Virus 100%
• Brain Protein 100%
• Kainic Acid-Induced Seizure 50%
• N Methyl-D-Aspartate Receptor 50%
• Epilepsy 50%
• Neuroprotective Agent 50%
• Autoimmunity 50%
• Transgene 50%
• Autoantibodies 50%
• Histocompatibility 50%
• Apoplexy 50%
• Single Drug Dose 50%
• Neurologic Disease 50%
• Brain Antigen 50%
• Humoral Immunity 50%
• Middle Cerebral Artery Occlusion 50%

Neuroscience

• Adeno-Associated Virus 100%
• Brain Protein 100%
• Transgene 50%
• Aspartic Acid 50%
• Epileptic Absence 50%
• Middle Cerebral Artery 50%
• Neurological Disorder 50%
• Brain Antigen 50%
• Neuroprotective Agent 50%
• Humoral Immunity 50%